You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 63 No. 7, July 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (33)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Neuro-ophthalmology
 •Neurology, Other
 •Drug Therapy
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic Disease)

Bianca Weinstock-Guttman, MD; Murali Ramanathan, PhD; Norah Lincoff, MD; Salvatore Q. Napoli, MD; Jitendra Sharma, MD; Joan Feichter, RN; Rohit Bakshi, MD

Arch Neurol. 2006;63:957-963.

Background  Neuromyelitis optica is a severe demyelinating disease that selectively involves the optic nerves and the spinal cord but usually spares the brain. It is considered to have a B-cell–induced pathogenesis. Mitoxantrone hydrochloride, a synthetic anthracenedione approved for worsening relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis, has been shown to primarily suppress the humoral response.

Objective  To evaluate the benefit of mitoxantrone treatment in patients with relapsing neuromyelitis optica.

Design  Prospective 2-year study.

Setting  Academic multiple sclerosis center.

Patients  Five patients (3 women and 2 men) with an age range of 20 to 51 years and an Expanded Disability Status Scale score of 2.5 to 6.5 (mean ± SD, 4.40 ± 1.88).

Interventions  Monthly intravenous infusions of mitoxantrone hydrochloride, 12 mg/m2, for 6 months followed by 3 additional treatments every 3 months.

Main Outcome Measures  Expanded Disability Status Scale score measured every 3 months and during relapses; findings on orbital, brain, and spinal cord magnetic resonance images performed at baseline and at 3, 6, 12, 18, and 24 months; and visual evoked potentials and results of ophthalmologic evaluations performed at baseline and annually.

Results  During the 2 years of treatment, 2 patients each had a relapse once within the initial 5 months of treatment (1 severe and 1 moderate). Improvement was seen clinically and on magnetic resonance images in 4 patients. Patients generally tolerated the treatment well, although 1 patient had a reversible decrease in cardiac ejection fraction.

Conclusion  Our results suggest a beneficial effect of mitoxantrone treatment for relapsing neuromyelitis optica.

Trial Registration  clinicaltrials.gov Identifier: NCT00304291


Author Affiliations: The William C. Baird Multiple Sclerosis Center, Jacobs Neurological Institute (Drs Weinstock-Guttman, Ramanathan, and Lincoff and Ms Feichter) and Department of Pharmaceutical Sciences (Dr Ramanathan), State University of New York, Buffalo; and Partners Multiple Sclerosis Center, Center for Neurological Imaging, Departments of Neurology and Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (Drs Napoli, Sharma, and Bakshi).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Relapsing neuromyelitis optica: long term history and clinical predictors of death
Cabre et al.
J. Neurol. Neurosurg. Psychiatry 2009;80:1162-1164.
ABSTRACT | FULL TEXT  

Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis
Green and Cree
J. Neurol. Neurosurg. Psychiatry 2009;80:1002-1005.
ABSTRACT | FULL TEXT  

Treatment of Neuromyelitis Optica With Mycophenolate Mofetil: Retrospective Analysis of 24 Patients
Jacob et al.
Arch Neurol 2009;66:1128-1133.
ABSTRACT | FULL TEXT  

Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder
Bonnan et al.
Mult Scler 2009;15:487-492.
ABSTRACT  

Treatment of Neuromyelitis Optica With Rituximab: Retrospective Analysis of 25 Patients
Jacob et al.
Arch Neurol 2008;65:1443-1448.
ABSTRACT | FULL TEXT  

Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica
Weinstock-Guttman et al.
Mult Scler 2008;14:1061-1067.
ABSTRACT  

Review: Treatment of neuromyelitis optica: Current debate
Okamoto et al.
Therapeutic Advances in Neurological Disorders 2008;1:43-52.
ABSTRACT  

Is Neuromyelitis Optica Eyeing a Distinct Path From Multiple Sclerosis?
Glisson and Galetta
Arch Ophthalmol 2008;126:128-129.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.